Friday, November 5, 10:00 – 11:15am Eastern Time (US and Canada)
2:00 – 3:15pm Greenwich Mean Time
7:30 – 8:45pm Indian Standard Time
Find your local time here.
Watch online here.
- Javier Guzman, Director of Global Health Policy and Senior Policy, CGD
- Nimalan Arinaminpathy, Professor of Mathematical Epidemiology, MRC Center for Global Infectious Disease Analysis, Imperial College London
- Sripad Devalkar, Associate Professor of Operations Management, Indian School of Business
- Sidharth Rupani, Senior Director, Global Impact (Engagement Management), Coupa Software
- Wanrudee Isaranuwatchai, Director of Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Thailand
- Justice Nonvignon, Head of Health Economics Unit, Africa Centres for Disease Control & Associate Professor and Health Economist at the School of Public Health, University of Ghana, Legon.
- Zulma Cucunubá, Associate Professor, Department of Epidemiology and Biostatistics at Pontificia Universidad Javeriana, Colombia
- Hiral Anil Shah, Senior Policy Analyst, Center for Global Development
ABOUT THE EVENT
Since the early days of the COVID-19 pandemic, many organizations have been using epidemiological and operational modelling to predict the spread of the novel coronavirus as well as estimate the impact of different control measures.
With the development of multiple vaccine candidates, new questions have now arisen as to how policymakers can ensure cost-effective COVID-19 vaccine deployment and allocation that considers both operational constraints (e.g., in-country cold chain or human resources for healthcare capacity) and epidemiological characteristics (e.g., seroprevalence, social mixing, age-stratification, comorbidities, vaccine stretching etc.,).
In this event, study groups will present and disseminate results that tackle a diverse range of research questions focusing on COVID19 vaccine deployment and allocation. A wider discussion will follow focusing on how decision makers can consider epidemiological and operational modelling evidence to inform cost-effective COVID-19 vaccine deployment and allocation and highlight potential future steps and generalisable lessons for low- and middle-income countries.